<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472563</url>
  </required_header>
  <id_info>
    <org_study_id>065-120606</org_study_id>
    <nct_id>NCT00472563</nct_id>
  </id_info>
  <brief_title>Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate</brief_title>
  <acronym>PROMEC</acronym>
  <official_title>Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Antioquia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Antioquia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deterioration of kidney renal function occurs in a minority of people due to
      contrast-required procedures. The purpose of this study is to compare two different
      interventions to reduce the risk of kidney injury after contrast medium exposition.

      We will perform a randomized clinical trial following a modification of a previously
      published protocol (Merten et al.JAMA 2004;291(19):2328-34). Patients will be randomly
      assigned to one of two groups of treatment. Group A will receive 1 cc/kg/hour of 0.9% saline
      infusion starting 12 hours before and continuing 12 hours after the procedure. Group B will
      receive 3 cc/kg of sodium bicarbonate solution for one hour prior to procedure, then drip
      rate will be decreased to 1 cc/kg/hour until 6 hours post procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will perform a randomized clinical trial following a modification of a previously
      published protocol (Merten et al.JAMA 2004;291(19):2328-34). Patients will be randomly
      assigned to one of two groups of treatment. Group A will receive 1 cc/kg/hour of 0.9% saline
      infusion starting 12 hours before and continuing 12 hours after the procedure. Group B will
      receive 3 cc/kg of sodium bicarbonate solution for one hour prior to procedure, then drip
      rate will be decreased to 1 cc/kg/hour until 6 hours post procedure.

      Phase 2/3 study Study Type: Interventional Study Design: Prevention, Randomized, Open Label,
      Active Control, Parallel Assignment, Efficacy Study.

      Subjects: Consecutive samples of all inpatients who meet the inclusion criteria

      Primary outcomes: Development of contrast induced nephropathy, defined as an increase in
      serum creatinine of 25% or more within 48 h after administration of contrast.

      Secondary outcomes: change in serum bicarbonate; change in serum potassium; change in serum
      creatinine.

      Expected total enrollment: 212

      Allocation Assignment: Patients who meet inclusion criteria and agree to participate in the
      study will be assigned by a random number table to saline or bicarbonate, using closed
      envelopes and stratifying according to history of diabetes and type of procedure (cardiac
      catheterism or others).

      Condition: Contrast Induced Nephropathy

      Intervention: 75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W

      Gender: both Age: 18+ years of age Recruitment Status: participants are currently being
      recruited

      Facility location:

      Universidad de Antioquia, Internal Medicine Department; Hospital Universitario San Vicente de
      Paul. Medellin, Colombia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>development of contrast induced nephropathy, defined as an increase in serum creatinine of 25% or more within 48 h after administration of contrast</measure>
    <time_frame>48 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in serum bicarbonate; change in serum potassium; change in serum creatinine</measure>
    <time_frame>48 h</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">212</enrollment>
  <condition>Acute Kidney Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicarbinate 150 mEq/L</intervention_name>
    <description>75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18+ years of age

          -  Inpatient at Hospital Universitario San Vicente de Paúl scheduled to undergo
             diagnostic CT scan using contrast or angiography and either

               -  Serum creatinine 1.2 mg/dl or more, or

               -  Type 2 Diabetes Mellitus

        Exclusion Criteria:

          -  Current clinical diagnosis of exacerbated congestive heart failure

          -  Exposure to contrast 30 days prior to study

          -  Allergy to contrast dye

          -  Chronic renal disease with dialysis therapy

          -  Acute renal failure with dialytic urgency

          -  Urgency procedure needed

          -  Systolic blood pressure &lt; 90 or vasopressor support

          -  No authorization by patient or physician in charge

          -  Serum potassium &lt; 3 mEq/L

          -  Ejection fraction &lt; 35% by previous echocardiography

          -  Acute pulmonary edema in previous 48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Wilmar A Maya Salazar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julián M Aristizábal, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oscar M Santos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John F Nieto, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liliana Jaramillo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge I García, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabian A Jaimes, MD</last_name>
    <role>Study Director</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alvaro García, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario San Vicente Paúl</name>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <zip>57</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2007</study_first_submitted>
  <study_first_submitted_qc>May 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2007</study_first_posted>
  <last_update_submitted>May 5, 2008</last_update_submitted>
  <last_update_submitted_qc>May 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2008</last_update_posted>
  <keyword>bicarbonate</keyword>
  <keyword>nephropathy</keyword>
  <keyword>contrast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

